The estimated Net Worth of Jon Sakoda is at least 267 百万$ dollars as of 27 June 2018. Jon Sakoda owns over 192,425 units of AVEO Pharmaceuticals Inc stock worth over 266,755,830$ and over the last 9 years Jon sold AVEO stock worth over 730,105$.
Jon has made over 10 trades of the AVEO Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Jon bought 192,425 units of AVEO stock worth 404,093$ on 27 June 2018.
The largest trade Jon's ever made was buying 6,000,000 units of AVEO Pharmaceuticals Inc stock on 28 March 2017 worth over 3,000,000$. On average, Jon trades about 916,041 units every 69 days since 2016. As of 27 June 2018 Jon still owns at least 17,783,722 units of AVEO Pharmaceuticals Inc stock.
You can see the complete history of Jon Sakoda stock trades at the bottom of the page.
Jon's mailing address filed with the SEC is 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM, MD, 21093.
Over the last 15 years, insiders at AVEO Pharmaceuticals Inc have traded over 6,664,465$ worth of AVEO Pharmaceuticals Inc stock and bought 153,034,058 units worth 217,351,881$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, AVEO Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of 9,488,415$. The most recent stock trade was executed by Michael P Bailey on 20 December 2022, trading 276,746 units of AVEO stock currently worth 1,248,124$.
AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
AVEO Pharmaceuticals Inc executives and other stock owners filed with the SEC include: